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Research
Persistent lipophilic xenobiotics pose particu-
lar methodologic challenges when assessing
potential human health risks. The human
health effects literature on exposure to
lipophilic agents such as organochlorines
(OCs) is equivocal, impairing our ability to
quantify risks (Calle et al. 2002; Hunter et al.
1997; Laden et al. 2001a, 2001b). For exam-
ple, Wolff and colleagues (Wolff 1985; Wolff
and Toniolo 1995; Wolff et al. 1993, 2000)
found an increased odds ratio for breast can-
cer for the highest quintile of wet-weight
dichlorodiphenyl-dichloroethylene (DDE)
and polychlorinated biphenyls (PCBs;
expressed as nanograms analyte per milliliter
serum) when compared with the lowest quin-
tile, whereas Laden et al. (2001a, 2001b)
found no association when concentrations of
DDE and PCBs were standardized for serum
triglycerides and cholesterol. No association
was reported for PCBs and risk of breast can-
cer when expressing concentrations either as
wet weight or lipid standardization values
(Helzlsouer et al. 1999).
Varying laboratory practices for express-
ing PCB concentrations may in part account
for the equivocal findings for human health
end points. Serum PCB concentrations, as
with other lipophilic xenobiotics, are depen-
dent on serum lipid concentrations (Eyster
et al. 1983; Guo et al. 1987). Under certain
circumstances an equilibrium is reached, and
information regarding serum PCB levels and
serum lipid levels may be predictive of PCB
body burden (Brown and Lawton 1984). If
serum lipids indeed act in this manner, higher
serum lipid levels should correspond to higher
serum PCB concentrations (Calvert et al.
1996). However, serum OC concentrations
and lipids are affected postprandially and need
to be considered in relation to quantity and
timing of food consumption (Phillips et al.
1989). When it is not possible to collect adi-
pose tissue, serum samples are frequently used.
However, serum (or plasma) introduces
methodologic challenges with regard to lipids
when estimating health risks, particularly when
nonfasting samples are used (Whitcomb et al.
2005). Collection of fasting samples can ham-
per the feasibility of epidemiologic research
and may adversely impact study participation.
Nonfasting samples require further attention
to serum lipids (Brown and Lawton 1984;
Brown et al. 1994; Eyster et al. 1983). 
Our limited understanding of the true
relation between serum and adipose tissue
concentrations of lipophilic xenobiotics in
relation to serum lipids and particular health
outcomes makes model speciﬁcation difﬁcult
(Calvert et al. 1996; Mussalo-Rauhamaa
1991). Investigators typically express measure-
ments on a wet-weight basis or per unit vol-
ume of serum or as lipid-standardized values,
where the concentration is divided by serum
lipids. 
Lipid standardization may be useful for
comparing exposure concentrations across tis-
sue specimens or across study populations by
expressing PCB concentrations per gram of
fat (Morgan and Roan 1970). Use of lipid
weight (PCB per unit of serum lipids) as
opposed to wet weight (PCB per unit of
serum) has been advocated for the measure-
ment of persistent lipophilic chemicals
(Brown and Lawton 1984), especially if one
assumes body burden equilibrium. Other
approaches reported in the literature include
the use of a log-linear model with serum
lipids included as a separate term in the
regression equation (Moysich et al. 1998).
Other investigators have conducted two-stage
analyses wherein serum lipids are regressed on
serum PCB concentrations with the residuals
entered as an individual risk factor (Hunter
et al. 1997).
The issue of how best to model the rela-
tion among serum PCBs, lipids, and health
outcomes remains an understudied area critical
for the assessment of health effects. Here we
demonstrate the impact of model (mis)speciﬁ-
cation and its effect on the interpretation of
study findings. We used directed acyclic
graphs (DAGs) to deﬁne a causal framework
among exposure, lipids, and health outcome
and values for parameters as informed by the
literature (Hernan et al. 2002; Robins et al.
2000). Using DAGs to supply a causal frame-
work and parameter values informed by the
literature, we present the results of a simula-
tion study. These results identify the best sta-
tistical model for each circumstance and the
bias produced by a mismatch between the
DAG and the statistical analysis.
Materials and Methods 
Statistical models and DAGs. Optimal model-
ing of the statistical relations among serum
PCBs, serum lipids, and health outcomes
requires positing an underlying causal model
that reflects the following considerations:
a) biologic plausibility; b) laboratory capability
for quantifying compounds and lipids;
c) underlying statistical assumptions (e.g., error
structure); and d) other relevant study covari-
ates (e.g., known and potential confounders).
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The literature on exposure to lipophilic agents such as polychlorinated biphenyls (PCBs) is con-
ﬂicting, posing challenges for the interpretation of potential human health risks. Laboratory varia-
tion in quantifying PCBs may account for some of the conﬂicting study results. For example, for
quantiﬁcation purposes, blood is often used as a proxy for adipose tissue, which makes it necessary
to model serum lipids when assessing health risks of PCBs. Using a simulation study, we evalu-
ated four statistical models (unadjusted, standardized, adjusted, and two-stage) for the analysis of
PCB exposure, serum lipids, and health outcome risk (breast cancer). We applied eight candidate
true causal scenarios, depicted by directed acyclic graphs, to illustrate the ramifications of mis-
speciﬁcation of underlying assumptions when interpreting results. Statistical models that deviated
from underlying causal assumptions generated biased results. Lipid standardization, or the divi-
sion of serum concentrations by serum lipids, was observed to be highly prone to bias. We con-
clude that investigators must consider biology, biologic medium (e.g., nonfasting blood samples),
laboratory measurement, and other underlying modeling assumptions when devising a statistical
plan for assessing health outcomes in relation to environmental exposures. Key words: causal mod-
eling, directed acyclic graphs, organochlorines, polychlorinated biphenyls, risk estimation, serum
lipids. Environ Health Perspect 113:853–857 (2005). doi:10.1289/ehp.7640 available via
http://dx.doi.org/ [Online 17 March 2005]To focus on bias, we assume perfect laboratory
measurement of PCBs and the absence of
unmeasured confounding.
We depict each scenario via a simple DAG
that shows relations but does not dictate a spe-
cific statistical model (i.e., mean and error
structures). A single-headed arrow represents a
causal relation between the ancestor (tail) and
the descendant (head). A dashed line repre-
sents a noncausal association between two
variables, suggesting a shared ancestor that
may or may not have been measured; the
absence of an arrow signiﬁes no relation.
The true causal structure relating PCBs
and serum lipids depends on the outcome
under study. Investigators typically have insuf-
ﬁcient biologic information to specify the cor-
rect analytic model, often resulting in analytic
strategies based on unveriﬁed assumptions. For
example, research indicates a possible causal
effect of PCBs on serum lipid levels (Hennig
et al. 2005; Langer et al. 2003). Additionally,
lipid levels have been suggested to affect breast
cancer risk (Atalay et al. 2004), but their
impact on other health end points has received
limited attention. For our purposes in this
study, our scenarios, hypothetical “causal
truths,” are based on the literature and their
relation to frequently used statistical models.
Statistical models. We investigated four
statistical models (unadjusted, standardized,
adjusted, and two-stage) for the analysis of
hypothesized PCB exposure, serum lipids,
and a health outcome (breast cancer), along
with eight plausible DAGs for each model to
illustrate the choices facing investigators. For
illustrative purposes, all models assume that
there are no unmeasured confounders. For all
models, P = Pr(Y = 1|X, SL), where Y is a
dichotomous dependent variable representing
the presence/absence of the disease; X = PCB;
and SL = serum lipids.
Unadjusted model. The unadjusted model
is equivalent to the use of wet-weight values
when estimating the effect of an exposure such
as PCBs on a health outcome without further
consideration of serum lipids. 
logit (P) = α1 + β1ln(x) [1]
Accordingly, this model is suitable for use
when it is reasonable to assume that serum
lipids are not a confounder. This assumption
holds true regardless of the relation between
lipids and the outcome. Inclusion or exclusion
of lipids as an adjustor may affect model fit,
but it will not impact PCB exposure/response
estimates. Four DAGs, shown in Figure 1, are
appropriately evaluated by use of the unad-
justed statistical model. Figure 1A reflects a
scenario that will result in an unbiased risk
estimate as serum lipids are assumed to be
unrelated to PCB levels. Use of this model for
Figure 1B yields optimal estimates, if serum
lipids are unrelated to both PCBs and the
outcome.
An unadjusted model is also appropriate
for Figure 1C, where PCBs are assumed to
have an indirect effect via serum lipids;
adjustment for a variable in the causal path-
way may introduce an undesirable bias when
estimating direct effects (Greenland 1996,
2003; Greenland and Morgenstern 2001). 
In Figure 1D, PCBs are assumed to affect
both serum lipids and the outcome, creating
a spurious association (Robins et al. 2000).
Here, only an unadjusted model is appropri-
ate for risk estimation. Because they vary
with PCBs, adjustment for serum lipids is
tantamount to partial adjustment for the
exposure itself.
Standardized model. The lipid-standard-
ized model is one way to account for the
effect of serum lipids on serum PCB levels.
This model is used frequently and is concep-
tually similar to use of the body mass index
(BMI; weight in kilograms divided by the
squared height in meters) to adjust weight for
height in measuring adiposity.
[2]
The power, m in Equation 2 is a factor that
generalizes the relation of PCBs and serum
lipids. Due to measurement error in the quan-
tification of lipids, use of Equation 2 when
Figure 1A holds can result in biased estimates.
If Figure 1B holds, estimates will be affected by
a scaling issue, as the beta coefﬁcient is that for
the log of the ratio of PCB to lipids. If the true
relations follow Figure 1 (C or D), then use of
Equation 2 will adjust, albeit incompletely, for
the exposure of interest, as in both Figure 1C
and D, PCBs determine the variance of serum
lipids. Figure 1C depicts a causal relation
between both PCBs and serum lipids with the
outcome, and a noncausal association between
PCBs and serum lipids resulting from a com-
mon ancestor, A. Use of the standardization
model will be valid for this situation only if the
standardization completely accounts for the
association between PCB and serum lipids.
Otherwise, use of this model will result in
biased estimates.
Figure 1F is modeled similarly to
Figure 1D in that the relation between PCBs
and lipids is due to a common cause, A. In
this scenario, the standardized model again
suffers from a scale issue. All other models
will produce unbiased estimates, but precision
of the estimate may vary depending on several
factors, including measurement error. The
potential error associated with the measure-
ment of serum lipids can exceed that for the
analyte itself (Needham and Wang 2002) and
is an important source of bias.
Figure 1G represents two possible circum-
stances in which serum PCBs are causally
related or correlated with the true exposure/
outcome association. If the relation between
serum and adipose concentration levels of
PCBs is governed by serum lipid levels, then
standardization may allow use of one as a
proxy for the other. 
Adjusted model. In the adjusted model,
there is an assumption that PCBs are not stan-
dardized for serum lipids, reﬂecting the absence
of an association between lipids and the study
outcome. Note that the standardized model is a
member of the family of adjusted models.
logit(P) = α3 + β3ln(X) + β4ln(SL) [3]
When comparing the lipid component in the
standardized model [ln(X) – m × ln(SL)] with
logit ln
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Figure 1. Causal scenarios for relations among PCB, serum lipids (SL), and outcome (Y). (A) PCB and SL
are marginally dependent conditional on Y; serum PCB (S-PCB) causes Y, and SL causes Y. (B) PCB as
cause of Y; S-PCB causes Y, independent of SL. (C) PCB and Y are marginally dependent on and blocked
by SL; S-PCB causes SL, which causes Y. (D) Y and SL are marginally dependent and blocked by serum
PCB; S-PCB causes Y and SL. (E) PCB and SL are marginally dependent conditional on both the shared
ancestor variable, A, and Y. An unmeasured variable, A, causes both S-PCB and SL, each of which inde-
pendently causes the outcome; this is the traditional situation of confounding, with SL acting as a con-
founder of the relation between serum PCBs, PCBs, and Y. (F) PCB and SL are marginally dependent on the
ancestor, A; SL and Y are marginally dependent on A and, thus effectively, on PCB. S-PCB and SL are
caused by A, but only PCB is causally related to Y. (G) PCB per unit SL and Y are marginally dependent
conditional on adipose tissue PCB. Adipose tissue PCB (A-PCB) causes serum PCB per unit serum lipid
and causes Y; PCB and outcome are correlated rather than directly causally related. (H) Blocked and
unblocked path. Y is both directly caused by PCB and marginally dependent conditional on SL; S-PCB
causes Y, as well as SL, which causes Y.the lipid term of the adjusted model [β4
ln(SL)], equivalent results are produced in that
β4 is forced to be equal to –m. If m is set equal
to 1, PCBs are divided by serum lipids, as is
the case with the standardized model.
However, the adjusted model is more ﬂexible
than the standardized model and, in general, is
applicable under the same set of assumptions. 
For Figure 1A, the adjusted model will
produce unbiased estimates without regard for
the degree of standardization, while the stan-
dardized model is conditional on standardiza-
tion being sufﬁcient. The adjusted model will
yield unbiased estimates for Figure 1A, B, D,
and F. For Figure 1C, E and H, the adjusted
model will yield biased estimates because the
adjustment is performed for a variable in the
causal pathway; for Figure 1H this bias is to
estimates of the total effect due to its parti-
tioning into direct and indirect.
Two-stage model. The two-stage model
includes the effects of PCBs and serum lipids
on the outcome:
ln(SL)=α + β5ln(X) + R
logit(P)= α4 + β6ln(X) + β7 × (R) [4]
Implications of the two-stage model arise
from its relation to the adjusted model. Both
the intercept and the beta coefficient in the
two-stage model are simple functions of the
parameters from the adjusted model and the
regression of serum lipids on log PCBs. The
coefﬁcient for the residual term, R, is precisely
that of the adjusted model’s lipids term: 
α4 = α3 – β4α
β6 = β3 – β5β4
β7 = β4
Use of the two-stage model for Figure 1A will
result in estimates similar to those produced
by the adjusted model, because there is no
assumption about an association between
PCBs and serum lipids. Therefore, the residu-
als will be equivalent to the lipid term in the
model. The two-stage model may also be used
to represent Figure 1F, with an important
caveat that the risk estimates now have a dif-
ferent interpretation in that they separate the
PCB effect from the lipid effect on the out-
come. In some circumstances, the two-stage
model will generate unbiased risk estimates for
Figure 1B, although they will be inefficient.
Similarly, the model may yield unbiased risk
estimates for Figure 1C although confounding
is not addressed. 
The two-stage model is appropriate when
it is important to distinguish direct and indi-
rect effects of PCBs (Figure 1H). In this sce-
nario, the effect of serum lipids is an indirect
effect via PCBs; their inclusion introduces bias
as is the case for the standardized model where
assumptions of causality may not be clearly
delineated.
Simulations. In addition to showing
causality in a statistical model, each DAG can
be used to guide model selection. We con-
ducted a simulation study to evaluate the util-
ity of various models for various scenarios
depicted by DAGs. We used the causal struc-
tures they deﬁne, assigned lognormal distribu-
tions for PCB and serum lipids, and assumed a
binomial outcome variable Y with Pr(Y = 1 |
PCB, serum lipids). For example, in Figure 1H
PCB causes disease Y and affects serum lipid
(which in turn also affects disease); these asso-
ciations motivate the model: 
ln(SL) = α0 + γ [ln(X)]
logit(P) = α1 + β1ln(X)
+ β2{E [ln(SL)|X]} 
= α0 + α1 + (β1 + β2γ)[ln(X)] [5]
The log odds [logit(P(X, SL)] equals an inter-
cept (α0), the prevalence among the unexposed,
plus the factor, β1+β2γ, by which PCB affects
the probability of the event. There is no serum
lipid term, denoting that there is no linear
inﬂuence of serum lipid levels. 
In Figure 1, the assumptive role of serum
lipids is variously a) an independent cause, b)a
dependent cause, c) an independent noncause,
d) a dependent noncause, and e) a modiﬁer. A
represents an unmeasured variable that is an
ancestor to both PCB and serum lipids (e.g.,
fish consumption) that may result in con-
founding (Hernan 2001, Hernan et al. 2002). 
Additionally, we assessed the effects of
serum lipid measurement error [ε∼N(0, σe
2)]
with different values of σe
2 and the relation
between PCB and serum lipids by varying the
strength of their linear relation, α, from the
linear regression, SL = α0+ αX. 
In these quantitative representations of
the DAGs, it is clear that magnitude of
effects, error, and bias will be functions of the
values chosen for the parameters. We set the
independent effect of PCB as a constant
(βlnPCB = 0.6 in the logistic regression model),
with approximate values taken from the liter-
ature (Wolff and Toniolo 1995). In our
unpublished data, we observed a significant
linear relation between total serum PCBs and
serum lipids with a regression coefficient
value of approximately 0.3. The values pro-
vided for the strength of the linear relation
between PCB, and serum lipids represented a
very weak association (α = 0.01) to a strong
association (α = 2.0).
Results
Table 1 displays the bias and mean square
error for estimates that result from the four
statistical models given the underlying causal
truths for σe
2 = 1, and α = 0.3. For Figure 1A,
which represents PCB and SL as independent
causes of the outcome, all models except the
standardized produce minimally biased esti-
mates. The standardized model results in a
biased underestimate of the PCB effect on
outcome. When SL is completely extraneous,
as in Figure 1B, bias occurs similar to the pre-
vious situation. Figure 1C depicts the effect of
PCB acting strictly through SL and is esti-
mated unbiasedly by the two-stage approach.
The unadjusted model produces minimal bias.
Adjustment for SL results in a large under-
estimate of effect, as does standardization,
though underestimates resulting from stan-
dardization are substantially greater (351%).
When SL is affected by PCB but does not
directly influence the outcome (Figure 1D),
standardization is the only modeling approach
with substantial bias, underestimating the true
effect by nearly 80%, whereas the other mod-
els are within 1% of the true effect. In the
confounded case, (Figure 1E), only the
adjusted model performed well. Lack of
adjustment failed to address the confounding
by SL, and standardization was not a sufﬁcient
method to account for this confounder. In
adjusting for serum lipids via the residuals, the
two-stage model misattributes the association
between PCB and SL as a causal link and
results in biased estimates of the effect of inter-
est—the total effect of PCB on risk. Figure 1F
represents a noncausal correlation between
PCB and SL and, as for Figure 1A, B, and D,
produced biased underestimates using the stan-
dardized model. Figure 1G is unique among
the DAGs in that it posits that serum levels of
PCB are dependent on levels in adipose, which
are in turn causally related to the outcome. In
Lipid adjustment and risk estimation
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Table 1. Percent bias of estimates of effect of PCBs on outcome for evaluated statistical models.
Percent bias (MSE)a
DAG (Figure 1) Unadjusted Standardized Adjusted Two-stage
A 1.2 (1.26) –51.3 (10.3) 1.8 (1.28) 1.8 (1.28)
B –0.8 (1.34) –75.9 (21.1) –0.7 (1.35) –0.7 (1.33)
C –15.4 (2.78) –351.3 (161.1) –99.4 (1.59) 1.1 (2.78)
D 0.4 (1.14) –79.8 (23.3) 0.8 (1.17) 0.5 (1.14)
E 24.0 (3.37) –128.8 (60.3) 0.1 (1.39) 27.2 (3.37)
F –0.4 (1.29) –85.0 (26.4) –0.1 (1.41) –0.3 (1.29)
G –86.3 (27.0) –1.0 (1.51) –1.0 (1.51) –85.9 (27.0)
H –11.2 (1.75) –128.3 (59.7) –25.4 (3.65) –8.7 (1.75)
Serum lipid measurement error distributed normally with mean 0, variance 1; α (strength of linear relation between log
PCB and log serum lipids) = 0.3; 500 repetitions; n = 1,000.
aMean square error multiplied by 100 for illustration (shown in parentheses).this situation, standardization functioned opti-
mally; the adjusted model produced similarly
unbiased estimates, while neither the unad-
justed nor two-stage model worked well.
Figure 1H represents a direct and indirect
causal link of PCB with outcome. The rela-
tion was modeled well by the unadjusted
(which estimates total effect) and the two-
stage (which separates total into estimated
direct and indirect) approaches. Adjustment
resulted in a small amount of bias, and stan-
dardization produced the most biased esti-
mates in this scenario.
The foregoing results indicate that the stan-
dardized and the adjusted models should be
compared. With the exception of Figure 1G,
the adjusted model produces smaller bias than
the standardized model. However, even under
conditions ideally suited for the standardized
model (Figure 1G: adipose PCB causes both
serum PCB per serum lipids and the out-
come), the adjusted model yielded a nearly
identically unbiased estimate. The two-stage
model produced results similar to those of the
unadjusted model, though less biased, for
Figure 1C, for which serum lipids are in the
causal pathway of PCBs and outcome.
Measurement error. To address the poten-
tial for measurement error accompanying
quantiﬁcation of serum lipids, an error term
with mean 0 and variance σe
2 was added to
the simulated distribution of serum lipids.
Figures 2–4 display bias as a function of this
measurement error at 4 values of α for each of
the models (unadjusted, standardized,
adjusted, and two-stage). Bias as a function of
σe
2 followed three distinct patterns among the
eight DAGs. Figure 2 displays the pattern for
Figure 1A, B, D, and F; with increasing
measurement error, bias was stable for the
unadjusted, adjusted, and two-stage models,
staying close to zero. For the standardized
model the relation between bias and σe
2 was
more complicated; bias increased with
measurement error when the relation between
PCB and lipids was weak, but at the highest
value of α evaluated, bias decreased with
measurement error. The value of σe
2 at the
inﬂection point varied from 0.5 for Figure 1F
to 3.0 for Figure 1A. 
Figure 3 displays the pattern of bias
observed when Figure 1C, E, and H depict
the truth. Similar to pattern 1, bias for the
standardized model varied in a nonlinear man-
ner, increasing for all values of α but the high-
est (α = 2). The adjusted and two-stage
models were essentially robust to measure-
ment error; however, both the unadjusted and
adjusted did not always produce unbiased esti-
mates of parameters for all underlying DAGs,
especially at different levels of α. A stronger
linear relation between PCB and lipids
resulted in greater bias in the adjusted model.
Bias of estimates produced by the unadjusted
model varied slightly with σe
2; for Figure 1C
and H bias increased slightly with increasing
measurement error (from 0 to 0.1 for 8, from
0 to 0.2 for 3). Increasing measurement error
in Figure 1E reduced bias as the strength of
the noncausal relation between PCBs and
serum lipids was altered by the variance in
serum lipids. 
Figure 4 displays bias for the four models
under the conditions represented by Figure 1G.
Both the standardized and adjusted models
produced unbiased estimates robust to
measurement error, whereas the unadjusted
and two-stage models produced biased esti-
mates that were equally prone to measurement
error. Changes in the strength of the linear
relation between PCB and lipids did not affect
bias for any of the four models in this scenario.
Discussion
We have described and evaluated four statisti-
cal models (unadjusted, standardized,
adjusted, and two-stage) commonly used to
assess the effects of lipophilic environmental
contaminants on human health when relying
on blood specimens for quantifying toxicant
concentrations. Our simulations show that
each statistical model has minimal bias for at
least the causal truth for which it is ideally
suited. Although most models performed well
under all but one causal scenario, the stan-
dardized model produced large biases for
most of the evaluated DAGs. The adjusted
model produced only a small bias even for the
DAG for which standardization is optimal.
We evaluated basic causal scenarios; the
eight DAGs we considered included only two
to four factors. When additional factors
impact levels of both PCB and serum lipids as
well as health outcome risk, the evaluation
will be more complex, and the trade-off
between statistical efficiency and robustness
will be more important. Although the
adjusted model produced consistently unbi-
ased estimates, there are circumstances where
adjustment (or stratiﬁcation) is inappropriate
and should be avoided. For example, adjust-
ment for a collider (an effect of two or more
other variables in the graph) has been demon-
strated to bias estimators of effect (Greenland
and Brumback 2002; Hernan et al. 2002).
Additionally, factors that share a common
cause will appear correlated in strata of that
common cause. Given an alleged relation
between PCB and serum lipids, their adjust-
ment might generate spurious associations if
an unmeasured factor is related to both serum
lipid levels and the outcome.
A discussion of causality, particularly when
regarding estimation of direct and indirect
causes, necessitates consideration of counter-
factuals. Consistent estimation of a direct or
indirect effect require at minimum the absence
of unmeasured confounding as well as the
assumptions of consistency and the existence of
a direct effect (Cole and Hernan 2002; Robins
2003). Estimation of causal effects and their
Schisterman et al.
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Figure 4. Bias as a function of measurement error
of serum lipids and strength of linear association of
PCB with serum lipids for Figure 1G. For this causal
diagram, the standardized and adjusted models
track together and are robust to both measurement
error and the strength of the linear relation
between PCB and serum lipid. The unadjusted and
two-stage models also track together and are
somewhat affected by increasing measurement
error, although not to changes in the strength of the
relation between PCB and serum lipid. The vertical
line at σe
2 = 1 signiﬁes the level used for Table 1.
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Figure 2. Comparison of bias for standardization
versus all other models as a function of measure-
ment error of serum lipids and strength of linear
association of PCB with serum lipids for Figure 1A,
B, D, and F. Bias for the standardized model was
systematically centered on −0.60 (100% underesti-
mation). As measurement error increased, the
impact of the strength of the relation between PCB
and serum lipid was reduced. None of the other
models were sensitive to measurement error under
any conditions of the PCB–serum lipid relation. The
vertical line at σe
2 = 1 signifies the level used for
Table 1.
Figure 3. Bias as a function of measurement error
of serum lipids and strength of linear association
of PCB with serum lipids for Figure 1C, E, and H.
The vertical line at σe
2 = 1 signiﬁes the level used
for Table 1.
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relations to DAGs is intimately tied to the
notion of counterfactuals. In reality, when a
factor impacts an outcome through both direct
and indirect pathways, we cannot observe the
direct effect in absence of the indirect effect,
and vice versa; their estimation depends on
counterfactual comparisons (Robins 2003). A
general counterfactual model has been pro-
posed that permits the estimation of total and
direct effects of ﬁxed and time-varying expo-
sures in longitudinal studies whether random-
ized or observational in design (Robins et al.
2000). However, a more detailed discussion is
beyond the scope of this paper.
Findings from our simulations demon-
strate that statistical models failing to uphold
underlying assumptions about causality lead to
biased results with implications for the inter-
pretation of effects of exposures on human
health end points. We speculate that equivocal
findings may arise, at least in part, from the
varying laboratory and analytic approaches for
specifying serum lipids when using nonfasting
blood specimens to estimate risk. Investigators
must remember to consider biology, biologic
medium, and laboratory methodology when
specifying a statistical model and its under-
lying assumptions appropriate for study.
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CORRECTION
Equation 4 was incorrect in the manuscript
originally published online but has been
corrected here.